

30 October, 2014

Quarterly Cashflow for Period Ended 30 September 2014

Melbourne, Australia: Wearable sensor medical device company dorsaVi Ltd (ASX. DVL) has today released its Appendix 4C – Quarterly Cashflow report for the period ended 30 September 2014.

The Company recorded cash receipts of \$117,000. Revenue for the quarter was \$236,000. Net operating cash outflow for the quarter was \$2.2 million. The Company has a strong balance sheet with a reported cash position of \$11,738,000.

Operational Update

OH&S

The Company is already starting to see the benefits of the Australian Workplace Compliance (AWC) acquisition in July. The acquisition enables dorsaVi to offer both new and existing clients a comprehensive suite of solutions to help reduce incidents and the severity of workplace injuries. The Occupational Health & Safety (OH&S) division has contributed revenue of \$169,000 in the quarter. This quarter, the Company signed contracts to undertake workplace assessments on the employees of a number of major companies including BP, Sodexo, Martin Brower, Kennards Hire, and Silver Chain. We expect to see further increase in OH&S receipts and revenue from next quarter as a result of these contracts.

ViMove

During the quarter, dorsaVi received 510K clearance by the US Food and Drug Administration (FDA) for measuring, recording, and reporting on movement and muscle activity of the lower back / lumbar spine allowing immediate launch of ViMove in the US. The company also received approval from Medsafe, the New Zealand Medicines and Medical Devices Safety Authority. ViMove is now available in Australia, New Zealand, US, Canada, UK and Europe.

ViPerform

The international profile of dorsaVi's products for the elite sports market continues to grow and is driving broad awareness across all markets. In July, dorsaVi made its first US sale of ViPerform to Metro Orthopaedics and Sports Therapy (MOST) in Washington DC. MOST is an internationally recognised sports medicine and performance practice, which provides comprehensive sports training and injury recovery programs for elite athletes and members of the general public. During the quarter a further two US clinics entered into ViPerform licence agreements.

Other new customers in the quarter include UK Barclays Premier League team, Sunderland Association Football Club, West Coast Eagles and Sao Paulo FC.

dorsaVi Chief Executive Officer Andrew Ronchi said: "It has been a productive first quarter and we are pleased with the foundations being laid for our expected rapid growth in US and Europe. Locally, acquiring AWC has already added substantial value to our OH&S business, which we expect will continue to drive sales in Australia during the next six months."

- ENDS -

For personal use only

For more information or to arrange an interview, contact:

MEDIA

Kellie Hanrick
Buchan Consulting
0413 681 346

khanrick@buchanwe.com.au

INVESTOR

Rebecca Wilson
Buchan Consulting
0417 382 391

rwilson@buchanwe.com.au

About dorsaVi

dorsaVi (ASX:DVL) is an ASX company focused on developing innovative motion analysis device technologies for use in elite sports, occupational health and safety, and clinical applications. dorsaVi believes its wearable sensor technology enables – for the first time – many aspects of detailed human movement and position to be accurately captured, quantified and assessed outside a biomechanics lab, in both real-time and real situations for up to 24 hours.

Our technology has applications across three sectors:

- **Clinical:** ViMove is transforming the management of patients by providing objective assessment, monitoring outside the clinic and immediate biofeedback. ViMove is currently used by medical and physiotherapy practices in Australia and the United Kingdom and is now available in the United States following FDA 510K clearance.
- **Elite Sports:** ViPerform is allowing coaches and medical teams managing elite athletes and teams to screen athletes and provide objective evidence for decisions on return to play, measure biomechanics and provide immediate biofeedback out on the field, tailor and track training programs and optimise technique and peak performance. ViPerform is being used by AFL and NRL clubs in Australia, clubs in the Barclays Premier League, Australian and Victorian Institutes of Sport, various Olympic teams and athletes internationally, and Cricket Australia.
- **OH&S:** We combine innovation, measurement and quality to reduce workplace incidents, costs, meet compliance and improve brand reputation. ViSafe enables employers to assess risk of injury for employees as well as test the effectiveness of proposed changes to workplace design, equipment or methods based on objective evidence. ViSafe has been used by major corporations including Coles, Woolworths, Toll, Toyota, Orora (formerly Amcor), Crown and BHP Billiton. Australian Workplace Compliance delivers risk mitigation through compliance to OHS, Quality Management Systems, Company Policy and Process.

Further information is available at www.dorsavi.com.

Appendix 4C

Quarterly report for entities admitted on the basis of commitments

Introduced 31/03/00 Amended 30/09/01, 24/10/05, 17/12/10

Name of entity

dorsaVi Ltd

ABN

15 129 742 409

Quarter ended ("current quarter")

September 2014

Consolidated statement of cash flows

Cash flows related to operating activities	Current quarter \$A'000	Year to date (3 months) \$A'000
1.1 Receipts from customers	117	117
1.2 Payments for (a) staff costs	(988)	(988)
(b) advertising and marketing	(252)	(252)
(c) research and development	(20)	(20)
(d) leased assets	0	0
(e) other working capital	(947)	(947)
1.3 Dividends received		
1.4 Interest and other items of a similar nature received	80	80
1.5 Interest and other costs of finance paid		
1.6 Income taxes paid		
1.7 Other (provide details if material)		
Net operating cash flows	(2,010)	(2,010)

+ See chapter 19 for defined terms.

For personal use only

Appendix 4C
Quarterly report for entities
admitted on the basis of commitments

	Current quarter \$A'000	Year to date (3 months) \$A'000
1.8 Net operating cash flows (carried forward)	(2,010)	(2,010)
Cash flows related to investing activities		
1.9 Payment for acquisition of:		
(a) businesses (item 5)	(120)	(120)
(b) equity investments		
(c) intellectual property	(43)	(43)
(d) physical non-current assets	(27)	(27)
(e) other non-current assets		
1.10 Proceeds from disposal of:		
(a) businesses (item 5)		
(b) equity investments		
(c) intellectual property		
(d) physical non-current assets		
(e) other non-current assets		
1.11 Loans to other entities		
1.12 Loans repaid by other entities		
1.13 Other (Payment for Term Deposit)		
	(190)	(190)
Net investing cash flows		
1.14 Total operating and investing cash flows	(2,200)	(2,200)
Cash flows related to financing activities		
1.15 Proceeds from issues of shares, options, etc.		
1.16 Proceeds from sale of forfeited shares		
1.17 Proceeds from borrowings		
1.18 Repayment of borrowings		
1.19 Dividends paid		
1.20 Other (Cost of raising capital)		
Other (Increase of loan to related entity)		
	0	0
Net financing cash flows		
Net increase (decrease) in cash held	(2,200)	(2,200)
1.21 Cash at beginning of quarter/year to date	13,938	13,938
1.22 Exchange rate adjustments to item 1.20		
1.23 Cash at end of quarter	11,738	11,738

+ See chapter 19 for defined terms.

For personal use only

Payments to directors of the entity and associates of the directors

Payments to related entities of the entity and associates of the related entities

		Current quarter \$A'000
1.24	Aggregate amount of payments to the parties included in item 1.2	187
1.25	Aggregate amount of loans to the parties included in item 1.11	n/a

1.26 Explanation necessary for an understanding of the transactions

The \$187k is made up of the following:

1. Salary and superannuation to CEO (director of the entity) and CTO (substantial shareholder of the entity) of \$80k
2. Reimbursement of business expenses to Pro-Active Industries Pty Ltd (an entity associated with the CEO) of \$14k
3. Reimbursement of business expenses to CEO & CTO of \$14k
4. Non Executive Directors' fees and expenses reimbursements of \$67k
5. Rent and related costs to Starfish Ventures Pty Ltd (an entity associated with Dr Panaccio, a director of the entity) of \$12k

Non-cash financing and investing activities

2.1 Details of financing and investing transactions which have had a material effect on consolidated assets and liabilities but did not involve cash flows

n/a

2.2 Details of outlays made by other entities to establish or increase their share in businesses in which the reporting entity has an interest

n/a

Financing facilities available

Add notes as necessary for an understanding of the position.

		Amount available \$A'000	Amount used \$A'000
3.1	Loan facilities	n/a	n/a
3.2	Credit standby arrangements	n/a	n/a

+ See chapter 19 for defined terms.

For personal use only

Reconciliation of cash

Reconciliation of cash at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts is as follows.	Current quarter \$A'000	Previous quarter \$A'000
4.1 Cash on hand and at bank	1,788	4,939
4.2 Deposits at call	9,950	9,000
4.3 Bank overdraft	n/a	n/a
4.4 Other (provide details)	n/a	n/a
Total: cash at end of quarter (item 1.23)	11,738	13,939

Acquisitions and disposals of business entities

	Acquisitions (Item 1.9(a))	Disposals (Item 1.10(a))
5.1 Name of entity	Australian Workplace Compliance Pty Ltd	n/a
5.2 Place of incorporation or registration	Victoria	n/a
5.3 Consideration for acquisition or disposal	\$120,000	n/a
5.4 Total net assets	\$14,370	n/a
5.5 Nature of business	Occupational Health & Safety Consultancy	n/a

Compliance statement

- 1 This statement has been prepared under accounting policies, which comply with accounting standards as defined in the Corporations Act (except to the extent that information is not required because of note 2) or other standards acceptable to ASX.
- 2 This statement does give a true and fair view of the matters disclosed.

Sign here: Date: 30 October 2014
 (Chief Financial Officer)

Print name: Jerome Whelan

For personal use only

Notes

1. The quarterly report provides a basis for informing the market how the entity's activities have been financed for the past quarter and the effect on its cash position. An entity wanting to disclose additional information is encouraged to do so, in a note or notes attached to this report.
2. The definitions in, and provisions of, AASB 107: Statement of Cash Flows apply to this report except for any additional disclosure requirements requested by AASB 107 that are not already itemised in this report.
3. **Accounting Standards.** ASX will accept, for example, the use of International Financial Reporting Standards for foreign entities. If the standards used do not address a topic, the Australian standard on that topic (if any) must be complied with.

+ See chapter 19 for defined terms.

For personal use only